Physician profile
Mark Schury
NPI 1376510099
$4,630.24
in general payments reported to CMS, 2019-2025
25 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $553 · 2021: $854 · 2022: $933 · 2023: $307 · 2024: $661 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $963.53 | 2019-2025 | Airsupra, Fasenra |
| Pfizer INC. | $494.52 | 2019-2023 | |
| Abbvie INC. | $438.30 | 2021-2023 | Vraylar |
| Genzyme Corporation | $260.34 | 2022-2024 | |
| Glaxosmithkline, LLC. | $248.20 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $220.64 | 2023-2024 | Zoryve |
| Novo Nordisk INC | $217.41 | 2020-2024 | Wegovy |
| Sunovion Pharmaceuticals INC. | $214.71 | 2019-2021 | |
| Allergan, INC. | $200.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $181.90 | 2020-2023 | Dificid, Delstrigo, Pifeltro |
| Lilly USA, LLC | $169.09 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.03 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $127.31 | 2019-2023 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.50 | 2025 | Trulance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $119.62 | 2019 | |
| Exact Sciences Corporation | $105.00 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $91.62 | 2022-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $47.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.03 | 2022 | |
| Supernus Pharmaceuticals, INC. | $22.98 | 2019-2022 | |
| Qiagen, LLC | $22.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.79 | 2023 | |
| Grifols USA, LLC | $18.29 | 2020 | |
| Amarin Pharma, INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.